Barcelona Liver Bioservices announces the oral presentation of a study using microfluidic human liver slices, revealing the antifibrotic effects of liraglutide through hepatic stellate cell deactivation and extracellular matrix remodeling.

Washington DC, November 7th 2025 Barcelona Liver Bioservices (BLB), a leading preclinical research organization specialized in liver disease modeling and drug discovery, is proud to

July 14, 2025 – Barcelona, Spain  Barcelona Liver Bioservices (BLB) is proud to announce the publication of a groundbreaking study in collaboration withGAT Therapeutics, presenting compelling